



AbbVie will present a total of **23 abstracts across several tumor types including brain cancer, hematologic malignancies, breast cancer, lung cancer and other solid tumors.**

Researchers will present efficacy and safety data on depatuxizumab mafodotin, an antibody-drug conjugate (ADC) being studied for the treatment of adults with amplified EGFR newly diagnosed or recurrent GBM. The most common genetic alteration in GBM, EGFR-amplification, occurs in approximately 50 percent of GBM patients.

Additional presentation include data from studies evaluating venetoclax - a BCL-2 inhibitor, co-developed by AbbVie and Genentech across multiple hematologic malignancies; ibrutinib - a BTK inhibitor, across multiple hematologic malignancies and chronic graft versus host disease (cGVHD); rovalpituzumab tesirine (Rova-T)- an ADC targeting delta-like protein 3 (DLL3)-expressing SCLC; veliparib- an oral PARP inhibitor, across multiple solid tumors; elotuzumab – a SLAMF7 targeting immunostimulatory antibody and other early-stage investigational compounds.

Key Trial Readouts

<p>Ibrutinib A BTK inhibitor in development for multiple hematologic malignancies and chronic graft versus host disease (cGVHD)</p>	<ul style="list-style-type: none"> • Long-Term Efficacy and Safety with Ibrutinib (ibr) in Previously Treated CLL: Up to Four Years Follow-Up of the RESONATE Study; Byrd et al.; Abstract 7510 • Ibrutinib vs Chlorambucil: Immunophenotypic and Quantitative Impacts on Circulating Immune Cells in Chronic Lymphocytic Leukemia (CLL); Solman et al.; Abstract 7524 • A Randomized, Double-Blind Phase III Study of Ibrutinib versus Placebo in Combination with Corticosteroids in Patients with New Onset Chronic Graft Versus Host Disease; Miklos et al.; Abstract TPS7072 • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab Versus Placebo in Combination with Rituximab in Patients with Treatment-Naïve Follicular Lymphoma (PERSPECTIVE); Fowler et al.; Abstract TPS7576
<p>Venetoclax BCL 2 inhibitor</p>	<ul style="list-style-type: none"> • Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax Combined with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia; Potluri et al.; Abstract TPS7069 • Phase 2, Open-Label Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma; Bueno et al.; Abstract TPS8056 • Venetoclax (VEN) in Patients with Relapsed Non-Hodgkin Lymphoma (NHL); Davids et al.; Publication
<p>Depatuxizumab mafodotin (ABT-414)</p>	<ul style="list-style-type: none"> • Efficacy Analysis of ABT-414 with or without Temozolomide (TMZ) in Patients (pts) with EGFR-Amplified, Recurrent Glioblastoma (rGBM) from a Multicenter, International Phase I Clinical Trial; van den Bent et al.; Abstract 2003;
<p>Rovalpituzumab tesirine (Rova-T)</p>	<ul style="list-style-type: none"> • A Phase III Study of Rovalpituzumab Tesirine Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients with Extensive Disease Small Cell Lung Cancer (ED SCLC); Komarnitsky et al.; Abstract TPS8583 • Molecular Profiling of Small Cell Bladder Cancer (SCBC) to Reveal Gene Expression Determinants of Aggressive Phenotype; Koshkin et al.; Abstract 4529 • A Study of Rovalpituzumab Tesirine in Frontline Treatment of Patients with DLL3 Expressing Extensive Small Cell Lung Cancer; Hann et al.; Abstract TPS2598 • An Open-Label Study of Rovalpituzumab Tesirine in Patients with DLL3-Expressing Advanced Solid Tumors; Kavalarchik et al.; Abstract TPS2597 • Rovalpituzumab Tesirine (Rova-T) as a Therapeutic Agent for Neuroendocrine Prostate Cancer (NEPC); Puca et al.; Abstract 5029

CORPORATE COMMUNICATIONS



“AbbVie’s data presentations at this year’s ASCO meeting reinforce our diverse and comprehensive oncology pipeline, focused on bringing new medicines to patients, especially in areas where few options exist in cancer,” said **Tom Hudson, M.D., vice president of oncology discovery and early development, AbbVie.** “By combining our deep knowledge in core areas of biology with cutting-edge technologies, and working together with our partners including scientists, industry peers and patients, we aim to discover and develop medicines that will drive transformational improvements in cancer treatment”

<p>Veliparib oral PARP inhibitor, across multiple solid tumors</p>	<ul style="list-style-type: none"> Phase 1/2 Study of Veliparib (V) Combined with Carboplatin (Cb) and Etoposide (E) in Patients (Pts) with Extensive-Stage Disease (ED) Small Cell Lung Cancer (SCLC) and Other Solid Tumors: Phase 1 Results; Atrafi et al.; Abstract 8530 Tolerability of Veliparib (V) in Combination with Carboplatin (C)/Paclitaxel (P): Based Chemoradiotherapy (CRT) in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC); Kozono et al.; Abstract 8546 Breast Conservation after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results from an International Randomized Trial (BrightNess); Golshan et al.; Abstract 514 Phase 3 Study Evaluating Efficacy and Safety of Veliparib (V) Plus Carboplatin (Cb) or Cb in Combination with Standard Neoadjuvant Chemotherapy (NAC) in Patients (Pts) with Early Stage Triple-Negative Breast Cancer (TNBC); Geyer et al.; Abstract 520
<p>Elotuzumab A SLAMF7 targeting immunostimulatory antibody</p>	<ul style="list-style-type: none"> Phase 3 ELOQUENT-2 Study: Extended Four-Year Follow-Up (FU) of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) vs Ld in Relapsed/Refractory Multiple Myeloma (RRMM); Lonial et al.; Abstract 8028 CheckMate 602: An Open-Label, Randomized, Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma; Lonial et al.; Abstract TPS8052
<p>ABBV-221</p>	<ul style="list-style-type: none"> Preliminary Results from a Phase 1 Study of the Antibody-Drug Conjugate ABBV-221 in Patients with Solid Tumors Likely to Express EGFR; Calvo et al.; Abstract 2510
<p>ABBV-399</p>	<ul style="list-style-type: none"> Phase I Study of ABBV-399, a c-Met Antibody-Drug Conjugate (ADC), as Monotherapy and in Combination with Erlotinib in Patients (Pts) with Non-Small Cell Lung Cancer (NSCLC); Angevin et al.; Abstract 2509; Impact of MET Inhibitors on Survival Among Patients (Pts) with MET Exon 14 Mutant (METdel14) Non-Small Cell Lung Cancer (NSCLC); Awad et al.; Abstract 8511
<p>ABT-348</p>	<p>Pharmaco-kinetics/dynamics (PK/PD) Evaluation and Individual Patient Cross-Over Studies with Growth Trajectory Assessment to Adaptively Develop Ilorasertib; Maitland et al.; Abstract 2563</p>